Microbubble tether for diagnostic and therapeutic applications

• US 10,052,394 B2
• Filed: 11/21/2014
• Issued: 08/21/2018
• Est. Priority Date: 11/21/2014
• Status: Active Grant

• Current Assignee: General Electric Company
• Original Assignee: General Electric Company
• Inventors: Butts, Matthew David, Castle, Jason William, Torres, Andrew Soliz, Roberts, Jeannette Christine, Kandapallil, Binil Itty Ipe
• Primary Examiner(s): Hartley, Michael G
• Assistant Examiner(s): Schlientz, Leah H
• Application Number:
  US14/550,689
• Publication Number:
  US 20160144059A1
• Time in Patent Office: 1,369 Days
• CPC Class Codes: A61K 49/223 Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/5052 Proteins, e.g. albumin

Abstract

The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Claims

1. A composition, comprising:

a microbubble comprising an albumin shell;

a therapeutic agent or a diagnostic agent; and

a moiety bound to the microbubble and to the therapeutic agent or the diagnostic agent, wherein the moiety hydrophobically binds preferentially to the microbubble relative to native albumin, and wherein the moeity is a cyanine 5 derivative comprising polyethyleneglycol units.

2. The composition of claim 1, wherein the therapeutic agent or the diagnostic agent comprises a small molecule drug, an oligonucleotide, or a large molecule.

3. The composition of claim 1, wherein the albumin shell comprises partially denatured, partially cross-linked human serum albumin.

4. The composition of claim 1, wherein the microbubble comprises a perfluoropropane core.

5. The composition of claim 1, wherein the microbubble has a diameter between about 1 μ

m to about 10 μ

m.

7. The composition of claim 1, wherein the cyanine 5 derivative comprises the following structures:

6. A composition, comprising:

a microbubble comprising an albumin shell;

a therapeutic agent or a diagnostic agent; and

a moiety bound to the microbubble and to the therapeutic agent or the diagnostic agent, wherein the moiety hydrophobically binds preferentially to the microbubble relative to native albumin, wherein the moeity is a cyanine 5 derivative, and wherein the cyanine 5 derivative comprises the following structure;